{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:50:25Z","timestamp":1779112225124,"version":"3.51.4"},"reference-count":22,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,13]]},"DOI":"10.31744\/einstein_journal\/2025rw1270","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:11:00Z","timestamp":1763129460000},"source":"Crossref","is-referenced-by-count":2,"title":["Off-label use of thalidomide in children with Crohn's disease and inflammatory bowel diseases"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-1923","authenticated-orcid":false,"given":"Laura Beatriz","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-7424","authenticated-orcid":false,"given":"Paula Lana de Miranda","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6767-7234","authenticated-orcid":false,"given":"Cristine de Ara\u00fajo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-3188","authenticated-orcid":false,"given":"Cristiane Aparecida Menezes","family":"de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16942","reference":[{"issue":"1","key":"key20251114141055_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","article-title":"Thalidomide: the tragedy of birth defects and the effective treatment of disease","volume":"122","author":"Kim","year":"2011","unstructured":"1 Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011;122(1):1-6. Erratum in: Toxicol Sci. 2012;125(2):613.","journal-title":"Toxicol Sci"},{"issue":"2","key":"key20251114141055_B2","first-page":"135","article-title":"Results of a double blind study of the influence of thalidomide on the lepra reaction","volume":"37","author":"Sheskin","year":"1969","unstructured":"2 Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis. 1969;37(2):135-46.","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"3","key":"key20251114141055_B3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/tera.1420380305","article-title":"Thalidomide update: regulatory aspects","volume":"38","author":"Kelsey","year":"1988","unstructured":"3 Kelsey FO. Thalidomide update: regulatory aspects. Teratology. 1988;38(3): 221-6.","journal-title":"Teratology"},{"issue":"11","key":"key20251114141055_B4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1286-4579(02)01645-3","article-title":"Thalidomide in the treatment of leprosy","volume":"4","author":"Teo","year":"2002","unstructured":"4 Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, et al. Thalidomide in the treatment of leprosy. Microbes Infect. 2002;4(11):1193-202.","journal-title":"Microbes Infect"},{"issue":"9","key":"key20251114141055_B5","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1590\/1413-81232021269.19462020","article-title":"Thalidomide control and use: are these appropriate to extend the use and mitigate the risk of teratogenicity in Brazil?","volume":"26","author":"Campos","year":"2021","unstructured":"5 Campos FT, et al. Thalidomide control and use: are these appropriate to extend the use and mitigate the risk of teratogenicity in Brazil? Cien Saude Coletiva, 2021;26(9):4233-42.","journal-title":"Cien Saude Coletiva"},{"key":"key20251114141055_B6","volume-title":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o RDC n\u00ba 11, de 22 de mar\u00e7o de 2011. Disp\u00f5e sobre o controle da subst\u00e2ncia talidomida e do medicamento que a contenha. Di\u00e1rio oficial da Rep\u00fablica Federativa do Brasil","author":"Brasil. Minist\u00e9rio da Sa\u00fade","year":"2011","unstructured":"6 Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o RDC n\u00ba 11, de 22 de mar\u00e7o de 2011. Disp\u00f5e sobre o controle da subst\u00e2ncia talidomida e do medicamento que a contenha. Di\u00e1rio oficial da Rep\u00fablica Federativa do Brasil. Bras\u00edlia (DF): Minist\u00e9rio da Sa\u00fade; 2011 [citado 2025 Mar 5]. Dispon\u00edvel em: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2011\/res0011_21_03_2011.html"},{"key":"key20251114141055_B7","volume-title":"Talidomida: 100 mg comprimido. Respons\u00e1vel t\u00e9cnico: Oliveira MAC","author":"Funda\u00e7\u00e3o Ezequiel Dias (FUNED)","year":"2021","unstructured":"7 Funda\u00e7\u00e3o Ezequiel Dias (FUNED). Talidomida: 100 mg comprimido. Respons\u00e1vel t\u00e9cnico: Oliveira MAC. Belo Horizonte: FUNED; 2021 [citado 2025 Abr 1]. Dispon\u00edvel em: https:\/\/www.funed.mg.gov.br\/wp-content\/uploads\/2022\/02\/bula-profissional-Funed-talidomida_rev-08.pdf"},{"issue":"8","key":"key20251114141055_B8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3109\/07853890108995961","article-title":"Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature","volume":"33","author":"Ginsburg","year":"2001","unstructured":"8 Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med. 2001;33(8):516-25.","journal-title":"Ann Med"},{"issue":"11","key":"key20251114141055_B9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/apt.13181","article-title":"Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease","volume":"41","author":"Yang","year":"2015","unstructured":"9 Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(11):1079-93.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"key20251114141055_B10","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/jcpt.13196","article-title":"Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: a systematic review","volume":"45","author":"Qiu","year":"2020","unstructured":"10 Qiu T, Li H, Sun T, Men P, Cui X, Liu C, et al. Thalidomide as a treatment for inflammatory bowel disease in children and adolescents: a systematic review. J Clin Pharm Ther. 2020;45(5):1134-42.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"key20251114141055_B11","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele","year":"2014","unstructured":"11 Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al.; European Crohn's and Colitis Organisation; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8(10):1179-207.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"key20251114141055_B12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2177\/jsci.28.92","article-title":"[Thalidomide therapy for infantile-onset Crohn's disease]","volume":"28","author":"Kabuki","year":"2005","unstructured":"12 Kabuki T, Ogimi C, Tanaka R, Ikematsu K, Joh K, Kagimoto S, Oh-Ishi T. [Thalidomide therapy for infantile-onset Crohn's disease]. Nihon Rinsho Meneki Gakkai Kaishi. 2005;28(2):92-8. Japanese.","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"issue":"4","key":"key20251114141055_B13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/jcpt.13140","article-title":"Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis","volume":"45","author":"Dipasquale","year":"2020","unstructured":"13 Dipasquale V, Tropeano A, Caime F, Romano C. Thalidomide for de novo Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. J Clin Pharm Ther. 2020;45(4):819-821.","journal-title":"J Clin Pharm Ther"},{"issue":"20","key":"key20251114141055_B14","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1001\/jama.2013.280777","article-title":"Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial","volume":"310","author":"Lazzerini","year":"2013","unstructured":"14 Lazzerini M, Martelossi S, Magazz\u00f9 G, Pellegrino S, Lucanto MC, Barabino A, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013;310(20):2164-73.","journal-title":"JAMA"},{"issue":"8","key":"key20251114141055_B15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1097\/MIB.0000000000000437","article-title":"effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomized clinical trial","volume":"21","author":"Lazzerini","year":"2015","unstructured":"15 Lazzerini M, Martelossi S, Magazz\u00f9 G, Pellegrino S, Lucanto MC, Barabino A, et al. effect of thalidomide on clinical remission in children and adolescents with ulcerative colitis refractory to other immunosuppressives: pilot randomized clinical trial. Inflamm Bowel Dis. 2015;21(8):1739-49.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"key20251114141055_B16","first-page":"178","article-title":"Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results","volume":"32","author":"Facchini","year":"2001","unstructured":"16 Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr. 2001;32(2):178-81.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"key20251114141055_B17","first-page":"522","article-title":"Thalidomide in Crohn disease and the risk of peripheral neuropathy","volume":"37","author":"Ahmed","year":"2003","unstructured":"17 Ahmed M, El-Hadi S, Jenkins HR. Thalidomide in Crohn disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr. 2003;37(4):522.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"key20251114141055_B18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","unstructured":"18 Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther. 2007;25(4):419-27.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"key20251114141055_B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MPG.0b013e318228349e","article-title":"Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab","volume":"54","author":"Felipez","year":"2012","unstructured":"19 Felipez LM, Gokhale R, Tierney MP, Kirschner BS. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. J Pediatr Gastroenterol Nutr. 2012;54(1):28-33.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"43","key":"key20251114141055_B20","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.3748\/wjg.v23.i43.7727","article-title":"Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis","volume":"23","author":"Wang","year":"2017","unstructured":"20 Wang L, Hong Y, Wu J, Leung YK, Huang Y. Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis. World J Gastroenterol. 2017;23(43):7727-34.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"key20251114141055_B21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jgh.14939","article-title":"Long-term outcomes of thalidomide in pediatric Crohn's disease","volume":"35","author":"Wang","year":"2020","unstructured":"21 Wang L, Xue A, Zheng C, Zhou Y, Wang Y, Huang Y. Long-term outcomes of thalidomide in pediatric Crohn's disease. J Gastroenterol Hepatol. 2020;35(7):1124-9.","journal-title":"J Gastroenterol Hepatol"},{"key":"key20251114141055_B22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jpeds.2016.07.040","article-title":"Longitudinal patterns of thalidomide neuropathy in children and adolescents","volume":"178","author":"Liew","year":"2016","unstructured":"22 Liew WK, Pacak CA, Visyak N, Darras BT, Bousvaros A, Kang PB. Longitudinal patterns of thalidomide neuropathy in children and adolescents. J Pediatr. 2016;178:227-32.","journal-title":"J Pediatr"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:11:04Z","timestamp":1763129464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/off-label-use-of-thalidomide-in-children-with-crohns-disease-and-inflammatory-bowel-diseases\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":22,"alternative-id":["10.31744\/einstein_journal\/2025RW1270"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025rw1270","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eRW1270"}}